Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02163889 · ClinicalTrials.gov registry record
Serial Therapeutic and Antifungal Monitoring Protocol
A clinical trial, sponsored by T2 Biosystems.
- Completed
- Registry status
- 31
- Enrollment target
NCT02163889: Completed study, sponsored by T2 Biosystems.
NCT02163889 is a clinical trial that has completed, run by T2 Biosystems. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02163889 has completed, sponsored by T2 Biosystems.
- COMPLETED
- Registry status
- 31 participants
- Enrollment target
Study Summary
The objective of this study is to investigate T2Candida performance as a monitoring tool for post-therapy clearance of Candida compared to blood culture. This study will collect a T2clinical specimen and companion blood culture from patients who have exhibited a positive blood culture by gram stain for yeast, and who are receiving treatment with antifungal therapy.
Primary Outcome
The number of days to a negative test result will be compared between the T2Candida Test and blood culture.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-09 |
| Est. Completion | 2017-04 |
What the finished NCT02163889 record still lists
NCT02163889 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 31 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02163889 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02163889 about?
NCT02163889 is a clinical study titled "Serial Therapeutic and Antifungal Monitoring Protocol". The objective of this study is to investigate T2Candida performance as a monitoring tool for post-therapy clearance of Candida compared to blood culture. This study will collect a T2clinical specimen and companion blood culture from patients who have exhibited a positive blood culture by gram stain...
What is the current status of trial NCT02163889?
This trial is currently completed. The enrollment target is 31 participants. The study started on 2014-09. Estimated completion is 2017-04.
Who is sponsoring clinical trial NCT02163889?
This trial is sponsored by T2 Biosystems, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia